×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Update on Presentation Materials for Webcast of Second Quarter Financial Results

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, announced that as part of its efforts to continuously improve its investor communications, it intends to provide a slide presentation with its upcoming second quarter financial results conference call, scheduled for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide presentation will be posted in the Investor section of the company's Web site (www.amgen.com/investors) in advance of the company's conference call. Amgen expects the slide presentation to be available on the Web site at or around the same time the company reports its second quarter financial results after the financial markets close.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Dan Whelan, 805-447-5995 (media)
Arvind Sood, 805-447-1060 (investors)
SOURCE: Amgen